Shotaro Nakajima

15PUBLICATIONS
22CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|May 14, 2026
Chemotherapy-induced cell cycle arrest is associated with increased claudin-18 isoform 2 expression and enhanced zolbetuximab-mediated cytotoxicity in gastric cancer.

|Aug 18, 2025
GALNT7 Stratifies dMMR/MSI Colorectal Cancer into Distinct Molecular Subsets Associated with Prognosis and PD-L1 Expression.

Hiroya Suzuki, Hirokazu Okayama, Shotaro Nakajima

|Feb 14, 2025
Activation of the tumor cell-intrinsic STING pathway induced by Fusobacterium nucleatum is associated with poor prognosis in esophageal cancer patients.

Shotaro Nakajima, Katsuharu Saito, Satoshi Fukai

|Aug 02, 2024
The impact of CLDN18.2 expression on effector cells mediating antibody-dependent cellular cytotoxicity in gastric cancer.

Akira Matsuishi, Shotaro Nakajima, Motonobu Saito

|May 25, 2024
TIM-3 Expression on Dendritic Cells in Colorectal Cancer.

Mei Sakuma, Masanori Katagata, Hirokazu Okayama

|May 11, 2024
TGFβ-Responsive Stromal Activation Occurs Early in Serrated Colorectal Carcinogenesis.

Hideaki Tsumuraya, Hirokazu Okayama, Masanori Katagata

Pageof 3

Frequent Collaborators

8 joint publications

Hirokazu Okayama

7 joint publications

Motonobu Saito

6 joint publications

Kosaku Mimura

2 joint publications

Kayoko Ishimaru